MedPath

Photodynamic diagnostic method using aminolevulinic acid against thoracic malignant tumors

Not Applicable
Conditions
Chest malignancy
Registration Number
JPRN-jRCTs011180023
Lead Sponsor
Kitada Masahiro
Brief Summary

We have developed an optical diagnostic method for pleural malignant lesions in combination with 5ALA, which is a photosensitive substance, and autofluorescence. As a result, localization diagnosis of lesions was possible, and pleural invasion factor could be diagnosed with sensitivity of 90.3% in the case of lung adenocarcinoma. It may contribute as a diagnostic method that complements conventional diagnostic imaging and visual diagnosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
267
Inclusion Criteria

1.Patients with chest malignancy (lung cancer, metastatic lung tumor, malignant breast tumor, thoracic lymph node metastasis from breast cancer) .
2.Surgical samples with diagnosis of chest malignancy on image or pathological diagnosis.
3.Cases requiring diagnosis by thoracoscopic biopsy including lymph nodes.
4.After receiving sufficient explanation about this exam, after understanding the sufficient understanding, cases where document agreement was acquired with the free will of the patient himself / herself.

Exclusion Criteria

1. Cases of pregnancy or lactation.
2. Patients with porphyria.
3. Drugs that are known to cause photosensitivity: tetracycline antibiotics, sulfonamide type preparations, new quinolone type antibacterial agents, hypericin (Hypericum perforatum extract), etc. St. John's Wort patients who are receiving food containing.
4. Cases with chronic hepatitis, chronic renalfailure.
5. Cases in which the result of treatment of malignant tumor does not change by this procedure.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath